Apadenoson Unit Dose Eliminates Weight-Based Calculation Errors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing methods of administering Apadenoson, a pharmacological stress agent, on a weight basis are prone to operator error and inefficiency due to the need for calculating and disposing of leftover doses, which can be mitigated by providing a unit dose independent of patient weight.
Innovation Solution
A unit dose of Apadenoson comprising the drug and a pharmaceutically acceptable carrier, specifically in the range of 76-175 µg, suitable for parenteral administration, eliminating the need for weight-based dosing and allowing for a single, standardized dose.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If weight-based dosing is used for Apadenoson administration, then the dose can be adjusted to patient weight, but operator error and inefficiency increase due to calculation requirements and leftover dose disposal
Solution Approach 1:
The patent divides the dosing approach into discrete unit doses (e.g., 100 µg vials) that can be administered independently of patient weight. Each unit dose is a fixed amount prepared in advance, eliminating the need for real-time weight-based calculations and reducing operator error while maintaining dosing accuracy through standardized preparations.
Solution Approach 2:
The patent changes the dosing parameter from continuous weight-based adjustment to discrete unit dose amounts. By establishing fixed unit doses (such as 100 µg) that correspond to specific weight ranges or are used universally, the system transforms a complex continuous parameter (weight) into a simple discrete parameter (unit dose count), thereby improving ease of operation while maintaining reliability.
2Adaptability or versatility
If weight-based dosing is used for Apadenoson, then dosing can be customized for each patient, but time is lost due to calculations and disposal of leftover agent
Solution Approach 1:
The patent prepares unit doses in advance with predetermined amounts (e.g., 100 µg vials) that are ready for immediate administration. This preliminary preparation eliminates the need for on-the-spot weight-based calculations and leftover dose disposal, as the correct dose is pre-measured and packaged. The unit doses can be selected based on patient weight ranges but are prepared beforehand, saving significant time during administration.
3Productivity
If unit dose is used for Apadenoson, then administration is simplified and time is saved, but dose response variability may occur across different weight patients
Solution Approach 1:
The patent establishes that a fixed unit dose (e.g., 100 µg) produces consistent peak coronary blood flow velocity across different patient weights. By changing from weight-based continuous dosing to fixed unit dose, the system achieves both high productivity (efficient administration) and reliable dose response consistency, as the unit dose amount is optimized to produce the desired pharmacological effect regardless of patient weight variations.
Data Source
Figure 1
Figure 2
AI summary
The present invention provides a unit dosage of Apadenoson, a pharmacological stress agent, and use of the same as a pharmacologic agent for myocardial perfusion imaging.